Ceribell, Inc. (CBLL) stock
CBLLNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30150% above fair value
$26.35−1.45 (-5.22%)
Close on Nov 12, 2026Market cap $1.01BP/E –Yield –
Ceribell EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Ceribell's EPS for the twelve months ending Jun 30, 2026 was -$1.76. For fiscal 2025 it was -$1.46.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$1.46 | – |
| FY2024 | Dec 31, 2024 | -$3.39 | – |
| FY2023 | Dec 31, 2023 | -$5.56 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$0.51 | – |
| Q1 FY2026 | Mar 31, 2026 | -$0.52 | – |
| Q4 FY2025 | Dec 31, 2025 | -$0.36 | – |
| Q3 FY2025 | Sep 30, 2025 | -$0.37 | – |
| Q2 FY2025 | Jun 30, 2025 | -$0.38 | – |
| Q1 FY2025 | Mar 31, 2025 | -$0.36 | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.85 | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.61 | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.56 | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.53 | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.32 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?